Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Academic Article uri icon

Overview

MeSH Major

  • Anticoagulants
  • Atrial Fibrillation
  • Benzimidazoles
  • Ischemic Attack, Transient
  • Stroke
  • Warfarin
  • beta-Alanine

abstract

  • Dabigatran appears to be cost-effective relative to warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Our analysis is limited by its reliance on data from a substudy of a single randomized trial, and our results may not apply in settings with uncommonly good international normalized ratio control using warfarin.

publication date

  • March 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1161/STROKEAHA.111.641027

PubMed ID

  • 22308255

Additional Document Info

start page

  • 881

end page

  • 3

volume

  • 43

number

  • 3